Nov 20, 09
|
| NEW STORY |
| 08:30 ET |
Dendreon Receives FDA Acknowledgement of Complete Response
|
|
Nov 11, 09
|
| 16:00 ET |
Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization
|
|
Nov 02, 09
|
| 08:30 ET |
Dendreon Completes Submission of Biologics License Application for PROVENGE
|
|
Oct 30, 09
|
| 07:30 ET |
Dendreon to Hold Conference Call on Wednesday, November 11, 2009 at 4:30 PM ET
|
|
Oct 29, 09
|
| 07:30 ET |
Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
|
|
Oct 12, 09
|
| 12:59 ET |
Dendreon Announces Election of Ian Clark and Pedro Granadillo to Board of Directors
|
|
Sep 24, 09
|
| 11:00 ET |
Dendreon Reports PROVENGE Regulatory and Commercialization Progress and Future Pipeline Plans at Analyst Event
|
|
Sep 04, 09
|
| 17:43 ET |
Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
|
|
Aug 27, 09
|
| 07:30 ET |
Dendreon Announces Analyst Day Webcast Presentation to be Held on September 24, 2009
|
|
Aug 11, 09
|
| 07:00 ET |
Dendreon Reports Second Quarter 2009 Financial Results
|
|
Aug 10, 09
|
| 15:49 ET |
Dendreon Signs Lease for New Manufacturing Facility in Atlanta
|
|
Jul 30, 09
|
| 07:30 ET |
Dendreon to Hold Conference Call on Tuesday, August 11, 2009 at 11:30 AM ET
|
|
Jun 05, 09
|
| 07:30 ET |
Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
|
|
May 14, 09
|
| 07:30 ET |
Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
|
|
May 13, 09
|
| 11:08 ET |
Dendreon Announces Closing of Common Stock Offering
|
|
May 08, 09
|
| 06:30 ET |
Dendreon Announces Common Stock Offering
|
|
May 07, 09
|
| 07:30 ET |
Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
|
|
May 06, 09
|
| 07:30 ET |
Dendreon Reports First Quarter 2009 Financial Results
|
|
Apr 28, 09
|
| 14:00 ET |
Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
|
|
| 11:30 ET |
Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
|
|
Apr 24, 09
|
| 07:30 ET |
Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
|
|
Apr 21, 09
|
| 07:30 ET |
Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
|
|
Apr 19, 09
|
| 10:00 ET |
Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
|
|
Apr 14, 09
|
| 08:30 ET |
PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
|
|
Apr 13, 09
|
| 17:41 ET |
Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
|
|
Mar 12, 09
|
| 16:27 ET |
Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
|
|
Feb 03, 09
|
| 07:30 ET |
Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
|
|
Jan 08, 09
|
| 07:30 ET |
Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
|
|
Nov 07, 08
|
| 07:30 ET |
Dendreon Reports Third Quarter 2008 Financial Results
|
|
Nov 06, 08
|
| 07:30 ET |
Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
|
|
Nov 05, 08
|
| 07:30 ET |
Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
|
|
Oct 23, 08
|
| 07:30 ET |
Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
|
|
Oct 06, 08
|
| 08:30 ET |
Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
|
|
| 07:00 ET |
Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
|
|
Sep 17, 08
|
| 07:30 ET |
Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
|
|
Aug 29, 08
|
| 07:30 ET |
Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
|
|
Aug 14, 08
|
| 07:30 ET |
Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
|
|
Aug 12, 08
|
| 07:30 ET |
Dendreon Reports Second Quarter 2008 Financial Results
|
|
Aug 07, 08
|
| 07:30 ET |
-Dendreon to Hold Conference Call on Tuesday, August 12, 2008 at 4:30 PM ET-
|
|
Jul 23, 08
|
| 07:30 ET |
Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
|
|
Jul 16, 08
|
| 07:30 ET |
Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
|
|
Jun 04, 08
|
| 07:30 ET |
Dendreon Announces Webcast Presentation at Needham 7th Annual Biotechnology and Medical Technology Conference
|
|
May 21, 08
|
| 07:30 ET |
Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
|
|
May 08, 08
|
| 07:00 ET |
Dendreon Reports First Quarter 2008 Financial Results
|
|
Apr 30, 08
|
| 07:30 ET |
Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
|
|
Apr 08, 08
|
| 18:00 ET |
Dendreon Announces Closing of Registered Direct Offering
|
|
Apr 03, 08
|
| 08:00 ET |
Dendreon Announces $47 Million Registered Direct Offering
|
|
Mar 13, 08
|
| 10:00 ET |
Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
|
|
Mar 12, 08
|
| 07:30 ET |
FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
|
|
Mar 06, 08
|
| 19:00 ET |
-Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
|
|
Mar 03, 08
|
| 11:21 ET |
Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
|
|
Feb 14, 08
|
| 07:30 ET |
Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
|
|
Feb 07, 08
|
| 07:30 ET |
Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
|
|
Jan 15, 08
|
| 07:00 ET |
Dendreon Receives European Patent Covering PROVENGE(R) and Company's ACI Platform Technology
|
|
Dec 07, 07
|
| 09:00 ET |
Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
|
|
Nov 15, 07
|
| 16:17 ET |
Dendreon Reports Third Quarter 2007 Financial Results
|
|
Nov 02, 07
|
| 09:00 ET |
-Dendreon to Hold Conference Call on Thursday, November 15, 2007 at 4:30 PM ET-
|
|
Oct 30, 07
|
| 09:00 ET |
Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
|
|
Oct 23, 07
|
| 07:00 ET |
Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
|
|
Oct 12, 07
|
| 07:00 ET |
Dendreon Secures $130 Million Committed Equity Financing Facility
|
|
Sep 18, 07
|
| 09:00 ET |
Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
|
|
Aug 17, 07
|
| 18:00 ET |
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
|
|
Aug 07, 07
|
| 16:00 ET |
Dendreon Reports Second Quarter 2007 Financial Results
|
|
Jul 17, 07
|
| 09:00 ET |
Dendreon to Hold Conference Call on Second Quarter 2007 Financial Results
|
|
Jun 11, 07
|
| 09:00 ET |
Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
|
|
Jun 06, 07
|
| 09:00 ET |
Dendreon Corporation Prices $75 Million Convertible Senior Subordinated Notes Offering
|
|
Jun 04, 07
|
| 07:00 ET |
Dendreon Corporation Announces Proposed $75 Million Convertible Senior Subordinated Notes Offering
|
|
May 31, 07
|
| 09:00 ET |
Dendreon Announces FDA Confirms Data Required for Provenge(R) Licensure
|
|
| 09:00 ET |
Dendreon Announces FDA Confirms Data Required for Provenge(R) Licensure
|
|
May 24, 07
|
| 09:00 ET |
Dendreon to Webcast Presentation at the Bank of America 2007 Health Care Conference
|
|
May 20, 07
|
| 18:30 ET |
Dendreon Announces Presentation of Data at American Urological Association Annual Meeting
|
|
May 10, 07
|
| 15:30 ET |
Dendreon Reports First Quarter 2007 Financial Results
|
|
May 09, 07
|
| 21:19 ET |
Dendreon to Hold Conference Call on Thursday, May 10, 2007 at 4:30 PM ET
|
|
| 05:30 ET |
Dendreon Receives Complete Response Letter From FDA for Provenge(R) Biologics License Application
|
|
Mar 29, 07
|
| 17:54 ET |
Dendreon Announces FDA Advisory Committee Reviewed Provenge(R) for Hormone Refractory Prostate Cancer
|
|
Mar 27, 07
|
| 09:00 ET |
Dendreon to Hold Post Advisory Committee Conference Call
|
|
Mar 14, 07
|
| 07:00 ET |
Dendreon Reports Fourth Quarter and Year End 2006 Financial Results
|
|
Mar 01, 07
|
| 06:00 ET |
Dendreon Announces FDA's Cellular, Tissue and Gene Therapies Advisory Committee to Review Provenge(R) for the Treatment of Asymptomatic, Metastatic, Androgen-Independent Prostate Cancer
|
|
Jan 16, 07
|
| 08:00 ET |
Dendreon's PROVENGE Granted FDA Priority Review for the Treatment of Asymptomatic, Metastatic, Androgen-Independent Prostate Cancer
|
|
Dec 14, 06
|
| 19:25 ET |
Dendreon Names Gregory T. Schiffman Chief Financial Officer
|
|
Nov 24, 06
|
| 09:00 ET |
Dendreon to Webcast Presentation at the Lazard Capital Markets Life Sciences Conference
|
|
Nov 16, 06
|
| 09:30 ET |
Dendreon Announces Registered Direct Common Stock Offering of $45 Million
|
|
Nov 13, 06
|
| 08:30 ET |
Dendreon Completes Submission of Biologics License Application to FDA for PROVENGE in Hormone Refractory Prostate Cancer
|
|
Nov 10, 06
|
| 08:20 ET |
Dendreon Announces New Data Analysis Presented at Chemotherapy Foundation Symposium
|
|
Nov 08, 06
|
| 09:00 ET |
Dendreon Announces Preliminary Results From PROTECT (P-11) Study
|
|
| 07:00 ET |
Dendreon Reports Third Quarter 2006 Financial Results
|
|
Oct 27, 06
|
| 09:00 ET |
Dendreon Presents New Data Correlating Potency of PROVENGE to Survival in Phase 3 Studies
|
|
Oct 25, 06
|
| 08:00 ET |
Dendreon to Host Conference Call on Third Quarter 2006 Financial Results
|
|
Oct 20, 06
|
| 07:00 ET |
Dendreon Announces New Data Analyses Presented at Prostate Cancer Foundation Scientific Retreat
|
|
Sep 20, 06
|
| 07:00 ET |
Dendreon Announces Upcoming Webcasts and Conference Participation
|
|
Aug 30, 06
|
| 08:30 ET |
Dendreon Announces Upcoming Webcasts and Conference Participation
|
|
Aug 24, 06
|
| 05:30 ET |
Dendreon Submits Clinical and Non-Clinical Sections of Rolling BLA to FDA for PROVENGE to Treat Advanced Prostate Cancer Patients
|
|
Aug 08, 06
|
| 09:30 ET |
Dendreon Reports Second Quarter 2006 Financial Results
|
|
Aug 01, 06
|
| 08:00 ET |
Dendreon Completes Construction of New Jersey Manufacturing Facility
|
|
Jul 25, 06
|
| 08:00 ET |
Dendreon to Host Conference Call on Second Quarter 2006 Financial Results
|
|
Jun 29, 06
|
| 18:00 ET |
Dendreon Announces Publication of Pivotal Phase 3 Study Highlighting Survival Benefit and Safety Profile of PROVENGE in Men With Advanced Prostate Cancer
|
|
Jun 12, 06
|
| 08:00 ET |
Dendreon to Webcast Presentation at the Needham Fifth Annual Biotechnology and Medical Technology Conference
|
|
Jun 07, 06
|
| 06:30 ET |
Dendreon Announces Publication of Research Showing Promising Activity of PROVENGE in Combination With Avastin in Patients With Recurrent Early Stage Prostate Cancer
|
|
May 15, 06
|
| 08:00 ET |
Dendreon Presents Data at American Association of Immunology Conference Highlighting Potential New Active Immunotherapy for Treatment of Renal Cell Cancer
|
|
May 12, 06
|
| 09:00 ET |
Dendreon to Webcast Presentation at the Bank of America 2006 Health Care Conference
|
|
May 09, 06
|
| 16:00 ET |
Dendreon Reports First Quarter 2006 Financial Results
|
|
Apr 26, 06
|
| 08:00 ET |
Dendreon to Host Conference Call on First Quarter 2006 Financial Results
|
|
Mar 23, 06
|
| 09:30 ET |
Dendreon Names Christopher Lockett Head of Government Affairs
|
|
Mar 17, 06
|
| 09:30 ET |
Dendreon to Webcast Presentation at Invest Northwest
|
|
Mar 16, 06
|
| 09:01 ET |
Dendreon Names Mark Frohlich Vice President of Clinical Affairs
|
|
Mar 13, 06
|
| 17:48 ET |
/FIRST ADD -- SFM094 -- Dendreon Corporation Earnings/
|
|
| 16:00 ET |
Dendreon Reports Fourth Quarter and Year End 2005 Financial Results
|
|
Mar 07, 06
|
| 09:30 ET |
Dendreon Names Ernest Bognar General Manager of Hanover, NJ Manufacturing Facility
|
|
Mar 03, 06
|
| 09:30 ET |
Dendreon to Webcast Presentation at Conference
|
|
Feb 28, 06
|
| 09:30 ET |
Dendreon to Host Conference Call on Fourth Quarter and Year-End 2005 Financial Results
|
|
Feb 09, 06
|
| 09:30 ET |
Dendreon CEO to Discuss PROVENGE at 'Cancer Immunotherapy Coming of Age' Panel at 2006 BIO CEO & Investor Meeting
|
|
Feb 02, 06
|
| 09:30 ET |
Dendreon Names Biotech Industry Veteran Mary Coon Vice President of Quality
|
|
Jan 20, 06
|
| 09:30 ET |
Dendreon Announces Strategic Realignment to Focus on PROVENGE BLA and Commercialization
|
|
Dec 12, 05
|
| 14:49 ET |
Dendreon Announces Exercise of Over-Allotment Option by Underwriters of Public Offering
|
|
Dec 07, 05
|
| 07:01 ET |
Dendreon Announces Pricing of Public Offering
|
|
Nov 29, 05
|
| 06:00 ET |
FDA Agrees to Special Protocol Assessment Amendment to D9902B 'IMPACT' Study of PROVENGE
|
|
Nov 28, 05
|
| 18:00 ET |
Dendreon Announces Public Offering of Common Stock
|
|
Nov 11, 05
|
| 09:30 ET |
Dendreon Announces Organizational Changes
|
|
Nov 07, 05
|
| 09:30 ET |
Dendreon Announces FDA Grants Fast Track Status for PROVENGE
|
|
Nov 04, 05
|
| 09:30 ET |
Dendreon Corporation Reports Third Quarter 2005 Financial Results
|
|
Nov 02, 05
|
| 16:32 ET |
Dendreon to Webcast Presentation at Conference
|
|
Oct 31, 05
|
| 07:02 ET |
Dendreon's Second Randomized Phase 3 D9902A Trial of PROVENGE Extends Survival in Patients with Advanced Prostate Cancer
|
|
Oct 28, 05
|
| 09:30 ET |
Dendreon to Announce Third Quarter 2005 Financial Results and Host Webcast Conference Call on November 4, 2005
|
|
Oct 03, 05
|
| 09:30 ET |
Dendreon Announces Data From Second Provenge Phase 3 Study D9902A to be Presented in Late-Breaking Session at ECCO Conference in Paris
|
|
Sep 21, 05
|
| 09:30 ET |
Dendreon Announces Modulation of Trp-p8 Significantly Inhibits Tumor Growth in Vivo
|
|
Sep 20, 05
|
| 09:01 ET |
Dendreon to Webcast Presentation at UBS Global Life Sciences Conference
|
|
Sep 14, 05
|
| 13:00 ET |
Dendreon Announces Plans to Submit Application for FDA Approval of Provenge for the Treatment of Advanced Prostate Cancer
|
|
Aug 18, 05
|
| 09:35 ET |
Dendreon Signs Agreement to Lease Manufacturing Facility in New Jersey
|
|
Aug 17, 05
|
| 09:35 ET |
Dendreon Appoints Michelle Burris Senior Vice President and Chief Financial Officer
|
|
Aug 08, 05
|
| 08:03 ET |
Dendreon Corporation Reports Second Quarter 2005 Financial Results
|
|
Aug 01, 05
|
| 19:23 ET |
Dendreon to Announce Second Quarter 2005 Financial Results and Host Webcast Conference Call on August 8, 2005
|
|
Jul 21, 05
|
| 09:35 ET |
Dendreon's Second Randomized Phase 3 D9902A Trial Shows Provenge Extends Survival in Patients With Advanced Prostate Cancer
|
|
Jun 21, 05
|
| 10:00 ET |
Dendreon Completes Enrollment in Phase 3 PROTECT (P-11) Clinical Trial of Provenge in Early Stage Prostate Cancer
|
|
Jun 10, 05
|
| 09:30 ET |
Dendreon Announces Senior Management Change
|
|
May 24, 05
|
| 09:01 ET |
Dendreon Announces Results of D9905 Phase 2 Study of Provenge in Patients with Early Stage Prostate Cancer
|
|
May 19, 05
|
| 08:01 ET |
Dendreon to Present at Scientific and Financial Conferences Next Week
|
|
May 14, 05
|
| 11:15 ET |
Dendreon D9901 Phase 3 Data Showing Provenge Significantly Improves Survival in Advanced Prostate Cancer Patients Presented at ASCO
|
|
May 09, 05
|
| 16:01 ET |
Dendreon Corporation Reports First Quarter 2005 Financial Results
|
|
May 05, 05
|
| 08:31 ET |
Dendreon Announces D9901 Phase 3 Study Results for Provenge Immunotherapy to be Presented at ASCO
|
|
May 02, 05
|
| 08:31 ET |
Dendreon to Announce First Quarter 2005 Financial Results and Host Webcast Conference Call on May 9, 2005
|
|
Apr 20, 05
|
| 16:30 ET |
Dendreon to Present at Invest Northwest 2005
|
|
Apr 18, 05
|
| 11:00 ET |
Trp-p8 Agonists Significantly Inhibit the Growth of Trp-p8 Expressing Tumors In Vivo
|
|
Mar 15, 05
|
| 16:15 ET |
Dendreon Corporation Reports Fourth Quarter and Year End 2004 Results
|
|
Mar 08, 05
|
| 09:00 ET |
Dendreon to Host Conference Call on Fourth Quarter and Year End 2004 Financial Results
|
|
Feb 23, 05
|
| 16:30 ET |
Dendreon to Present at Wells Fargo Securities Healthcare Conference
|
|
Feb 19, 05
|
| 19:00 ET |
Dendreon Reports Combination of Provenge and Avastin Impacts PSA Doubling Time In Patients With Biochemically-Relapsed Prostate Cancer
|
|
Feb 17, 05
|
| 07:01 ET |
Dendreon Announces Provenge Significantly Improves Survival in Men With Advanced Prostate Cancer
|
|
Jan 21, 05
|
| 08:02 ET |
Dendreon to Present at Piper Jaffray Healthcare Conference
|
|
Jan 11, 05
|
| 07:00 ET |
Dendreon Reports Preliminary D9902A Trial Data For Provenge in Patients With Advanced Prostate Cancer
|
|
Jan 05, 05
|
| 08:03 ET |
Dendreon to Present at JPMorgan Healthcare Conference
|
|
Dec 11, 04
|
| 08:00 ET |
Dendreon's APC8024 Immunotherapy Shows Promise in Advanced Breast Cancer
|
|
Dec 08, 04
|
| 08:00 ET |
Dendreon Corporation Further Strengthens Management Team
|
|
Nov 23, 04
|
| 15:00 ET |
Dendreon to Present at Lazard Life Sciences Conference
|
|
Nov 17, 04
|
| 08:03 ET |
Dendreon Corporation Names Rick Hamm General Counsel
|
|
Nov 16, 04
|
| 08:01 ET |
Dendreon to Host Webcast
|
|
Nov 09, 04
|
| 16:00 ET |
Dendreon Corporation Reports Third Quarter 2004 Financial Results
|
|
| 08:03 ET |
Dendreon Names James Caggiano as Vice President, Sales and Marketing
|
|
Nov 03, 04
|
| 09:00 ET |
Dendreon to Host Conference Call on Third Quarter 2004 Financial Results
|
|
| 08:31 ET |
Dendreon Achieves Commercial Scale of Antigen for Provenge
|
|
Oct 28, 04
|
| 06:02 ET |
Dendreon's Phase 3 D9901 Trial Shows Provenge Extends Survival in Patients With Advanced Prostate Cancer
|
|
Oct 27, 04
|
| 17:01 ET |
Dendreon Corporation to Host Conference Call Thursday, October 28, 2004
|
|